Development of a High-Throughput Screening Assay for Inhibitors of Aggrecan Cleavage Using Luminescent Oxygen Channeling (AlphaScreen™)

Abstract

Aggrecan is one of the most important structural components of joint cartilage, and members of the metalloprotease (MMP) and ADAM (a disintegrin and metalloproteinase) protease families have been shown to degrade aggrecan in vivo. A robust assay for aggrecan-degrading activity suitable for high-throughput screening (HTS) was set up and measured using AlphaScreen™. In this technology, beads brought into proximity through cross-linking and stimulated with laser light generate a signal through luminescent oxygen tunneling, the outcome of which is a time-resolved fluorescent signal. Specific antibodies to the carbohydrate side chains of aggrecan were harnessed to create a scaffold whereby aggrecan could form a cross-link between donor and acceptor AlphaScreen detector beads. Digested aggrecan, which failed to form a cross-link, generated no signal, so that inhibitors of the digestion could be detected as a restoration of signal. The development of this assay and its validation for HTS are described in this report. (Journal of Biomolecular Screening 2003:136-148)

References

1. Arner EC, Pratta MA, Deccico CP, et al: Aggrecanase: a target for the design of inhibitors of cartilage degradation . Ann NY Acad Sci 1999;878: 92-99 .

2. Mort JS, Billington CJ: Articular cartilage and changes in arthritis: matrix degradation . Arthritis Res 2001;3: 337-341 .

3. Fosang AJ, Last K, Mackiewicz RA: Aggrecan is degraded by matrix metalloproteinases in human arthritis: evidence that matrix metalloproteinase and aggrecanase activities can be independent . J Clin Invest 1996;98: 2292-2299 .

4. Tortorella MD, Burn TC, Pratta MA, et al: Purification and cloning of Aggrecanase-1: a member of the ADAMTS family of proteins . Science 1999;284: 1664-1666 .

5. Caterson B, Flannery CR, Hughes CE, Little CB: Mechanisms involved in cartilage proteoglycan catabolism . Matrix Biol 2000;19: 333-343 .

6. Bottomley KM, Borkakoti N, Bradshaw D, et al: Inhibition of bovine nasal cartilage degradation by selective matrix metalloprotease inhibitors . Biochem J 1997;15: 483-488 .

7. Buttle DJ, Handley CJ, Ilic MZ, et al: Inhibition of cartilage proteoglycan release by a specific inactivator of cathepsin B and an inhibitor of matrix metalloproteinases: evidence for two converging pathways of chondrocytemediated proteoglycan degradation . Arthritis Rheum 1993;36: 1709-1717 .

8. Cawston TE, Ellis AJ, Humm G, et al: Interleukin-1 and Oncostatin M in combination promote the release of collagen fragments from bovine nasal cartilage in culture . Biochem Biophys Res Commun 1995;215: 377-385 .

9. Fosang AJ, Last K, Gardiner P, et al: Development of a cleavage-site-specific monoclonal antibody for detecting metalloproteinase-derived aggrecan fragments: detection of fragments in human synovial fluids . Biochem J 1995;310: 337-343 .

10.

10. Hughes CE, Caterson B, Fosang AJ, et al: Monoclonal antibodies that specifically recognize neoepitope sequences generated by "aggrecanase" and matrix metalloproteinase cleavage of aggrecan: application to catabolism in situ and in vitro . Biochem J 1995;305: 799-804 .

11.

11. Bartnik E, Eidenmueller B, Buettner F, et al: Artificial recombinant substrate (rAGG1) and native aggrecan to determine the proteolytic activity of "aggrecanase" in cell culture systems. US patent 5872209 (assignee: Hoechst), 1999.

12.

12. Doughty JR, Goldberg RL, Ganu V, et al: A stromelysin assay for the assessment of metalloprotease inhibitors on human aggregated proteoglycan . Agents Actions 1993;39: C151-C153 .

13.

13. Westling J, Fosang AJ, Last K, et al: ADAMSTS4 cleaves at the aggrecanase site (Glu373-Ala374) and secondarily at the matrix metalloprotease site (Asn341-Phe342) in the aggrecan interglobular domain . J Biol Chem 2002;277: 16059-16066 .

14.

14. Horber C, Buttner FH, Kern C, et al: Truncation of the amino-terminus of the recombinant aggrecan rAgg1mut leads to reduced cleavage at the aggrecanase site: efficient aggrecanase catabolism may depend on multiple substrate interactions . Matrix Biol 2000;19: 533-543 .

15.

15. Tortorella MD, Pratta M, Liu RQ, et al: Sites of aggrecan cleavage by recombinant human aggrecanase-1 (ADAMTS-4) . J Biol Chem 2000;275: 18566-18573 .

16.

16. Tortorella MD, Pratta M, Liu RQ, et al: The Thrombospondin motif of aggrecanase-1 (ADAMSTS-4) is critical for aggrecan substrate recognition and cleavage . J Biol Chem 2000;275: 25791-25797 .

17.

17. Liebman J, Goldberg R: Current Protocols in Pharmacology. New York: John Wiley , 2001.

18.

18. MacPherson LJ, Bayburt EK, Caparelli MP, et al: Discovery of CGS27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits . J Med Chem 1997;40: 2525-2532 .

19.

19. Montgomery PC, Peppard JV, Skandera CA: A comparison of lymphocyte subset distribution in rat lacrimal glands with cells from tissues of mucosal and non-mucosal origin . Curr Eye Res 1990;9: 85-93 .

20.

20. Shalinsky DR, Brekken J, Zou H, et al: Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials . Ann NY Acad Sci 1999;878: 236-270 .

21.

21. Sills MA, Weiss D, Pham Q, et al: Comparison of assay technologies for a tyrosine kinase assay generates different results in high throughput screening . J Biomol Screen 2002;7: 191-214 .